1887

Abstract

Current practice guidelines recommend that pulmonary blastomycosis be treated with antifungal agents such as amphotericin B and itraconazole. Echinocandins are not recommended because of poor activity against and lack of supporting clinical data. We report a case of chronic pulmonary blastomycosis treated successfully with caspofungin.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.036103-0
2011-12-01
2020-01-23
Loading full text...

Full text loading...

/deliver/fulltext/jmm/60/12/1875.html?itemId=/content/journal/jmm/10.1099/jmm.0.036103-0&mimeType=html&fmt=ahah

References

  1. Antony S.. ( 2004;). Use of the echinocandins (caspofungin) in the treatment of disseminated coccidioidomycosis in a renal transplant recipient. . Clin Infect Dis 39:, 879–880. [CrossRef][PubMed]
    [Google Scholar]
  2. Bariola J. R., Perry P., Pappas P. G., Proia L., Shealey W., Wright P. W., Sizemore J. M., Robinson M., Bradsher R. W. Jr. ( 2010;). Blastomycosis of the central nervous system: a multicenter review of diagnosis and treatment in the modern era. . Clin Infect Dis 50:, 797–804. [CrossRef][PubMed]
    [Google Scholar]
  3. Bradsher R. W.. ( 1996;). Histoplasmosis and blastomycosis. . Clin Infect Dis 22: (Suppl. 2), S102–S111. [CrossRef][PubMed]
    [Google Scholar]
  4. Bradsher R. W., Bariola J. R.. ( 2011;). Blastomycosis. . In Essentials of Clinical Mycology, , 2nd edn., pp. 337–348. Edited by Kauffman C. A., Pappas P. G., Sobel J. D., Dismukes W. E... New York:: Springer;.
    [Google Scholar]
  5. Chapman S. W., Dismukes W. E., Proia L. A., Bradsher R. W., Pappas P. G., Threlkeld M. G., Kauffman C. A.. ( 2008;). Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. . Clin Infect Dis 46:, 1801–1812. [CrossRef][PubMed]
    [Google Scholar]
  6. Chen J., Song X., Yang P., Wang J.. ( 2009;). Appearance of anaphylactic shock after long-term intravenous itraconazole treatment. . Ann Pharmacother 43:, 537–541. [CrossRef][PubMed]
    [Google Scholar]
  7. CLSI ( 2008a;). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard, 2nd edn. M38-A2. . Wayne, PA:: Clinical and Laboratory Standards Institute;.
  8. CLSI ( 2008b;). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard, 3rd edn. M27-A3. . Wayne, PA:: Clinical and Laboratory Standards Institute;.
  9. De Pauw B., Walsh T. J., Donnelly J. P., Stevens D. A., Edwards J. E., Calandra T., Pappas P. G., Maertens J., Lortholary O. et al. & other authors ( 2008;). Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. . Clin Infect Dis 46:, 1813–1821. [CrossRef][PubMed]
    [Google Scholar]
  10. Espinel-Ingroff A.. ( 1998;). Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. . J Clin Microbiol 36:, 2950–2956.[PubMed]
    [Google Scholar]
  11. Galgiani J. N., Ampel N. M., Blair J. E., Catanzaro A., Johnson R. H., Stevens D. A., Williams P. L..on behalf of the Infectious Diseases Society of America ( 2005;). Coccidioidomycosis. . Clin Infect Dis 41:, 1217–1223. [CrossRef][PubMed]
    [Google Scholar]
  12. González G. M., Tijerina R., Najvar L. K., Bocanegra R., Luther M., Rinaldi M. G., Graybill J. R.. ( 2001;). Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model. . Antimicrob Agents Chemother 45:, 1854–1859. [CrossRef][PubMed]
    [Google Scholar]
  13. Janssen ( 2011;). Product Monograph – Sporanox. . Toronto:: Janssen Inc;.
  14. Kralt D., Light B., Cheang M., MacNair T., Wiebe L., Limerick B., Sarsfield P., Hammond G., MacDonald K. et al. & other authors ( 2009;). Clinical characteristics and outcomes in patients with pulmonary blastomycosis. . Mycopathologia 167:, 115–124. [CrossRef][PubMed]
    [Google Scholar]
  15. Nakai T., Uno J., Ikeda F., Tawara S., Nishimura K., Miyaji M.. ( 2003;). In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. . Antimicrob Agents Chemother 47:, 1376–1381. [CrossRef][PubMed]
    [Google Scholar]
  16. Pinto A., Chan R. C.. ( 2009;). Lack of allergic cross-reactivity between fluconazole and voriconazole. . Antimicrob Agents Chemother 53:, 1715–1716. [CrossRef][PubMed]
    [Google Scholar]
  17. Saccente M., Woods G. L.. ( 2010;). Clinical and laboratory update on blastomycosis. . Clin Microbiol Rev 23:, 367–381. [CrossRef][PubMed]
    [Google Scholar]
  18. Sarosi G. A., Davies S. F., Phillips J. R.. ( 1986;). Self-limited blastomycosis: a report of 39 cases. . Semin Respir Infect 1:, 40–44.[PubMed]
    [Google Scholar]
  19. Sugar A. M., Liu X. P.. ( 1996;). In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. . Antimicrob Agents Chemother 40:, 1314–1316.[PubMed]
    [Google Scholar]
  20. Sugar A. M., Liu X. P.. ( 2001;). Efficacy of voriconazole in treatment of murine pulmonary blastomycosis. . Antimicrob Agents Chemother 45:, 601–604. [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.036103-0
Loading
/content/journal/jmm/10.1099/jmm.0.036103-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error